MDMarc DiSabella

Marc DiSabella

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marc DiSabella has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Peripheral Nerve Blocks in the Treatment of Pediatric Headaches

    by Elizabeth Pickup, Merve Ozge Aktop, Emily McCracken, Alana Kravitz, James E. Bost, Alexandra B. Kornbluh, Mrinmayee Takle, Raquel Langdon, Marc DiSabella, Jeffrey Strelzik

  • Onabotulinumtoxin A is an effective preventative treatment of chronic and daily pediatric migraine

    by Lauren Vilardo, Elizabeth Pickup, Merve Ozge Aktop, Emily McCracken, Mrinmayee Takle, Raquel Langdon, Marc DiSabella, Alexandra B. Kornbluh, Jeffrey Strelzik

  • Coenzyme Q10 Supplementation May Be Correlated With Resolution of New Daily Persistent Headache

    by Mrinmayee Takle, Jeffrey Strelzik, Raquel Langdon, Abigail Turner, William McClintock, John Barber, Armelle Dejoie, Emily McCracken, Olivia Goucher, Marc DiSabella

    New daily persistent headache is a chronic, treatment-resistant primary headache disorder with limited guidance on effective management. Despite its significant impact on headache-related quality of life, few studies have identified targeted therapies that contribute to symptom resolution. This study aims to describe the outcomes of pediatric patients diagnosed with new daily persistent headache and assess associations between specific interventions and headache resolution. A retrospective review was conducted using data from a patient registry at Children's National Hospital. Patients diagnosed with new daily persistent headache were included. Demographic characteristics, clinical features, prior treatments, and resolution rates were analyzed. Statistical comparisons were made between patients who experienced headache resolution and those with persistence of headache. A total of 182 pediatric patients were included (mean age: 15.5 years; 78% female). Headache resolution occurred in 47 patients (25.8%). For patients whose new daily persistent headache resolved, coenzyme Q10 (CoQ10) supplementation was the only treatment that reached statistical significance, being more frequently administered in the resolved group compared with the nonresolved group (17% vs 4%, P = .010). Additional treatments approaching statistical significance during resolution of new daily persistent headache included magnesium ( P = .086), topiramate ( P = .112), and onabotulinum toxin A injections ( P = .179). Patients who engaged in regular exercise showed a trend toward higher resolution rates ( P = .058). CoQ10 supplementation may play a role in new daily persistent headache resolution, with potential benefit from exercise, magnesium, topiramate, and onabotulinum toxin A injections approaching significance. Further prospective studies and randomized controlled trials are needed to establish causality and optimize treatment strategies for pediatric new daily persistent headache.

  • Open Access

    Pediatric Headache Experience During the COVID-19 Pandemic

    by Marc DiSabella, Emily Pierce, Emily McCracken, Aarane Ratnaseelan, Lauren Vilardo, Kelsey Borner, Raquel Langdon, Angela A. Fletcher

    Objective: Headache disorders are exceedingly common in children and adolescents. The association between headaches, emotional stress, and disruptions in daily routines are well established. The goal of this study is to compare the experiences of patients with a preexisting diagnosis of a primary headache disorder in terms of headache frequency and severity, lifestyle techniques for headache prevention, screen use, and mood from before and after the onset of the COVID-19 pandemic. Methods: Patients evaluated by the Headache Clinic at Children’s National Hospital between Summer 2020 and Winter 2021 were enrolled in a patient registry. Patients completed a questionnaire examining changes in headache characteristics and lifestyle factors since the onset of the COVID-19 pandemic. Results: A total of 107 patients completed the survey. Since the pandemic’s onset, patients reported decreased physical activity (n = 59, 55%), increased frequency of chronic headaches from 40% (N = 42) to 50% (N = 54), and increased constant daily headaches from 22% (n = 24) to 36% (n = 38). Patients reported worsened anxiety (n = 58, 54%), mood (n = 50, 47%), and workload (n = 49, 46%). Sixty-one percent (n = 65) of patients reported using screens for school for more than 6 hours per day. The majority (n = 67, 63%) of patients indicated that they would prefer attending in-person school, with 14% (n = 15) responding that they preferred online school. Conclusion: Since the COVID-19 pandemic’s onset, pediatric headache patients have experienced increasing headache frequency, worsening anxiety and mood, decreased physical activity, and increased screen usage. Although this study is limited by sample size and observational design, future population-based studies will further elucidate the impact of this pandemic on pediatric headache.